Knott David M Jr Purchases 21,823 Shares of AtriCure, Inc. $ATRC

Knott David M Jr lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 88.6% during the 2nd quarter, Holdings Channel reports. The firm owned 46,443 shares of the medical device company’s stock after purchasing an additional 21,823 shares during the quarter. AtriCure comprises 0.7% of Knott David M Jr’s portfolio, making the stock its 24th biggest holding. Knott David M Jr’s holdings in AtriCure were worth $1,522,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Teacher Retirement System of Texas increased its position in AtriCure by 5.4% during the second quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after buying an additional 385 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of AtriCure by 7.5% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 11,016 shares of the medical device company’s stock worth $361,000 after acquiring an additional 766 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of AtriCure by 15.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 5,808 shares of the medical device company’s stock worth $190,000 after acquiring an additional 770 shares during the last quarter. US Bancorp DE raised its stake in AtriCure by 98.1% in the 1st quarter. US Bancorp DE now owns 1,593 shares of the medical device company’s stock valued at $51,000 after acquiring an additional 789 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in AtriCure by 1.0% during the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ATRC has been the subject of a number of research reports. Needham & Company LLC raised their target price on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 30th. BTIG Research set a $54.00 price objective on shares of AtriCure in a research report on Wednesday, July 30th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $52.22.

AtriCure Stock Up 3.8%

Shares of NASDAQ ATRC opened at $32.90 on Monday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -53.93 and a beta of 1.56. The stock’s fifty day moving average is $35.20 and its 200 day moving average is $33.96. AtriCure, Inc. has a 52 week low of $28.29 and a 52 week high of $43.11. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The firm had revenue of $134.27 million for the quarter, compared to the consensus estimate of $131.25 million. During the same period in the prior year, the company posted ($0.17) earnings per share. The business’s revenue for the quarter was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Sell-side analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Activity at AtriCure

In related news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $37.00, for a total value of $185,000.00. Following the transaction, the director directly owned 34,374 shares of the company’s stock, valued at $1,271,838. This trade represents a 12.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Justin J. Noznesky sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $36.30, for a total transaction of $108,900.00. Following the transaction, the insider owned 83,964 shares of the company’s stock, valued at approximately $3,047,893.20. This represents a 3.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,000 shares of company stock worth $473,900 in the last quarter. 3.50% of the stock is currently owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.